Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. will release its financial results for the first quarter of 2024 on May 8, 2024, focusing on mRNA medicines for infectious diseases and rare liver and respiratory diseases.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024.

Arcturus Therapeutics First Quarter 2024 Earnings Conference Call

• Wednesday, May 8, 2024 @ 4:30 p.m. ET
• Domestic: 1-888-886-7786
• International: 1-416-764-8658
• Conference ID: 96934019
• Webcast: Link

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240425873170/en/

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

VP, Head of IR/PR/Marketing

IR@ArcturusRx.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

When will Arcturus Therapeutics report its first-quarter financial results for 2024?

Arcturus Therapeutics will report its first-quarter financial results on May 8, 2024.

What time will the conference call and webcast be held on May 8, 2024?

The conference call and webcast will be held at 4:30 pm Eastern Time on May 8, 2024.

What is the ticker symbol for Arcturus Therapeutics Holdings Inc.?

The ticker symbol for Arcturus Therapeutics Holdings Inc. is ARCT.